The US FDA has scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for Monday to Tuesday, November 20-21, 2017. The Committee will review substances nominated for the list of bulk substances allowed for compounding and products nominated for the difficult to compound list. The Committee will receive updates on certain issues, following up on discussions from previous meetings, including quality standards and conditions at certain compounding facilities.